Incyte Corporation (INCY) reported third-quarter 2024 adjusted earnings of $1.07 per share, which missed the Zacks Consensus Estimate of $1.12. The company recorded earnings of $1.10 per share in the year-ago quarter. Total revenues in the reported quarter were $1.14 billion, which grew 23.8% year over year, driven by the sustained performance of its lead drug, Jakafi (ruxolitinib), and increased sales of Opzelura (ruxolitinib) cream on strong launch and demand. The top line beat the Zacks Consensus Estimat ...

Incyte (INCY) reported $1.14 billion in revenue for the quarter ended September 2024, representing a year-over-year increase of 23.8%. EPS of $1.07 for the same period compares to $1.10 a year ago.The reported revenue represents a surprise of +4.47% over the Zacks Consensus Estimate of $1.09 billion. With the consensus EPS estimate being $1.12, the EPS surprise was -4.46%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street e ...

Incyte (INCY) came out with quarterly earnings of $1.07 per share, missing the Zacks Consensus Estimate of $1.12 per share. This compares to earnings of $1.10 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -4.46%. A quarter ago, it was expected that this specialty drugmaker would post earnings of $0.78 per share when it actually produced a loss of $1.82, delivering a surprise of -333.33%.Over the last four quarters, the compa ...

Exhibit 99.1 https://files.reportify.cc/med FOR IMMEDIATE RELEASE Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs – Total revenues of $1,138 million in the third quarter (Q3'24) (+24% Y/Y) – Jakafi (ruxolitinib) net product revenues of $741 million in Q3'24 (+16% Y/Y); raising full year 2024 Jakafi guidance to a new range of $2,740 - $2,770 million ® – Opzelura (ruxolitinib) cream net product revenues of $139 million in Q3'24 (+52% Y/Y); launch momentum cont ...

Incyte Corporation (INCY) is scheduled to report third-quarter 2024 results on Oct. 29, before the opening bell.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Shares of Incyte have risen 3.9% in the year-to-date period against the industry’s decline of 1.8%.Image Source: Zacks Investment ResearchLet’s see how things might have shaped up prior to the announcement.Factors to NoteIncyte primarily derives product revenues from the sales of its lead drug, Jakafi (ruxolitinib), in the Un ...

Shares of Incyte (INCY) have risen 12.7% in the past six months against the industry's decline of 0.5%. The stock has also outperformed the sector and the S&P 500 during this time frame. The outperformance can be attributed to positive data readouts and new drug approvals. Lead drug Jakafi (ruxolitinib) also maintains momentum. INCY Outperforms Industry, Sector and S&P 500 Image Source: Zacks Investment Research INCY's Lead Drug Jakafi Maintains Momentum Incyte's lead drug, Jakafi, is a JAK1/JAK2 inhibitor ...

– Trial met its primary endpoint across all dose cohorts with 74% of patients at the 0.3 mg/kg every 2 weeks dose achieving a complete or partial response within the first six months of treatment – – Niktimvo approved by U.S. FDA for the treatment of chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg – – Niktimvo added to latest NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the treatme ...

Truist Securities has downgraded Incyte Corporation INCY, noting Jakafi's (ruxolitinib) patent loss approaching in 2028. Jakafi is Incyte's top-selling drug. It is indicated for polycythemia vera in adults, intermediate or high-risk myelofibrosis in adults, and steroid-refractory acute graft versus host disease in adult and pediatric patients. In second quarter 2024, the drug generated sales of $705.9 million, +3% year-over-year, driven by a 9% increase in paid demand. The analyst downgraded the stock from ...

Incyte (INCY) announced new data from a phase I study on pipeline candidate INCB123667 in patients with advanced solid tumors. INCB123667 is a highly selective, potential first-in-class CDK2 inhibitor. The new data was presented during a mini-oral presentation at the European Society of Medical Oncology. The updated data highlight the potential of the candidate as a differentiated treatment option for cancers with increased cyclin E1 activity, amplification and/or overexpression in cells predictive of CDK2 ...

It has been about a month since the last earnings report for Incyte (INCY) . Shares have added about 0.9% in that time frame, underperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Incyte due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Incyte's Q2 Earnings Lag Estimates, Revenues Top Inc ...